Condition: Advanced Solid Tumor · Advanced Malignant Neoplasm · Metastatic Cancer · Sponsor: PMV Pharmaceuticals, Inc
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
This description comes directly from the study's public registry record.
PMV Pharma Clinical Study Information Center · (609) 235-4038 · clinicaltrials@pmvpharma.com
Always discuss trial participation with your own doctor first.
| University of California Irvine Chao Family Comprehensive Cancer Center | Irvine, California, United States | Withdrawn |
| University of San Diego Moores Cancer Center | La Jolla, California, United States | Not Yet Recruiting |
| UCLA Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Rocky Mountain Cancer Center | Denver, Colorado, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Medical Oncology Hematology Consultants | Newark, Delaware, United States | Recruiting |
| University of Miami - Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
| Advent Health | Orlando, Florida, United States | Recruiting |
| Florida Cancer Specialists South | Port Charlotte, Florida, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
+ 65 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04585750